Status:
COMPLETED
Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hypertension
Lead Sponsor:
Allergan
Conditions:
Glaucoma
Ocular Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study evaluates the safety and efficacy of brimonidine 0.1% ophthalmic solution compared with brimonidine 0.2% ophthalmic solution in patients with glaucoma or ocular hypertension
Eligibility Criteria
Inclusion
- Ocular hypertension or glaucoma in both eyes
Exclusion
- Uncontrolled systemic disease
- Known allergy or sensitivity to brimonidine
Key Trial Info
Start Date :
May 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2004
Estimated Enrollment :
433 Patients enrolled
Trial Details
Trial ID
NCT00652483
Start Date
May 1 2003
End Date
September 1 2004
Last Update
April 3 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Atlanta, Georgia, United States